🧠机器之心•較早收集於 21m
Isomorphic Labs推出超越AlphaFold 3的IsoDDE
#drug-discovery#protein-prediction#binding-affinityisoddeisomorphic-labsisoddealphafold3deepmind
💡Proprietary AI doubles AlphaFold3 accuracy on drug-protein binding; spots novel pockets for undruggable targets
⚡ 30-Second TL;DR
有什麼變化
IsoDDE在蛋白質-配體基準測試準確率是AlphaFold 3兩倍
為什麼重要
透過精準低成本預測複雜相互作用，加速藥物發現，為以往無藥靶點開啟療法。專有性限制開放研究，但顯示DeepMind商業推進。
下一步行動
Review the IsoDDE technical report at https://zenodo.org/records/18606681 to benchmark against AlphaFold3 for protein modeling.
誰應關注：Researchers & Academics
關鍵要點
- •IsoDDE在蛋白質-配體基準測試準確率是AlphaFold 3兩倍
- •結合親和力預測優於Boltz-2及物理方法
- •僅用胺基酸序列識別大腦蛋白新型隱蔽位點
- •模擬超出訓練數據的誘導擬合及隱蔽囊
- •提升抗體-靶標相互作用預測，支持高價值療法
🧠 深度解析
背景與延伸：來自公開資料，非原文內容。引用 6 個來源。
🔑 增強重點摘要
- •Isomorphic Labs was spun out from DeepMind in 2021 to apply AlphaFold technology commercially to drug discovery.
- •In 2024, Isomorphic Labs established major research collaborations with Novartis and Eli Lilly to advance AI-driven drug programs.
- •The company raised $600 million in April 2025 in its first external funding round, led by Thrive Capital, to build its drug design engine.[1]
🔮 前景展望AI analysis grounded in cited sources
Isomorphic Labs will launch human trials for AI-designed drugs by late 2026
Company president stated in July 2025 they are preparing to start human trials after good progress on internal oncology and immunology programs.[1]
⏳ 時間線
2020-12
DeepMind releases AlphaFold2, solving protein folding challenge
2021-11
Isomorphic Labs founded as DeepMind spin-out for AI drug discovery
2024-05
Signs collaborations with Novartis and Eli Lilly
2024-11
DeepMind releases AlphaFold3
2025-04
Raises $600M in first external funding round
2025-07
Announces preparations for human trials of AI-designed drugs
📎 來源 (6)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
📰
AI 週報
閱讀本週精選 AI 大事摘要 →
👉相關動態
AI 策展新聞聚合。所有內容版權歸原始發布者所有。
原始來源： 机器之心 ↗
每週 AI 簡報
每週一封，可隨時退訂。